Choosing a Lu-177 PSMA Treatment Center in India: How to Evaluate Quality, Credentials, Track Record, and Cost

If you have metastatic castration-resistant prostate cancer - called mCRPC - and a PSMA-positive PET scan, you may be a candidate for Lu-177 PSMA therapy. This is a targeted radioligand therapy that delivers radiation directly to prostate cancer cells carrying the PSMA protein. Because it's unavailable or very expensive in many countries - including much of the GCC, parts of Africa, and some US and UK private settings - patients increasingly travel to India to access it. But choosing where to get this treatment shouldn't be based on cost alone. The hospital's quality, the nuclear medicine team's experience, and the safety systems in place all affect how well this therapy works.

This guide gives you a practical checklist. It covers what credentials to look for, what questions to ask, what red flags to watch for, and how to compare hospital costs without compromising quality.

Why India has become a destination for Lu-177 PSMA therapy

Lutetium Lu-177 vipivotide tetraxetan - brand name Pluvicto - received US FDA approval in March 2022 for adults with PSMA-positive mCRPC who had progressed after both hormone therapy and taxane-based chemotherapy. The pivotal VISION trial showed that adding Lu-177 PSMA therapy to best standard of care improved median overall survival from 11.3 months to 15.3 months, with a hazard ratio of 0.62 - a 38% reduction in the risk of death compared to best supportive care alone. The FDA expanded this approval in March 2025 to include patients who had received hormone therapy but not yet had chemotherapy, based on the Phase III PSMAfore trial results.

India has developed expertise in this field. Several major hospitals started Lu-177 PSMA programs before FDA approval, giving their nuclear medicine teams years of hands-on experience. The cost per cycle in India is much lower than in the United States, Australia, or most European private settings. For patients from countries where insurance doesn't cover this treatment or where it's not yet licensed, India offers a practical option. If you want to understand what the full patient journey looks like, the article on how international patients access Lu-177 PSMA treatment in India covers the practical steps from eligibility scan to follow-up.

Eight quality markers to look for in any Lu-177 PSMA center

Use these criteria as a checklist when you research hospitals or speak with a coordinator. A center with genuine experience in this therapy will meet all of them.

1. AERB licensing for therapeutic radiopharmaceuticals

The Atomic Energy Regulatory Board (AERB) is India's authority for licensing facilities that handle radioactive materials, including Lu-177. Any center that legally administers this therapy in India must hold a valid AERB license for therapeutic radiopharmaceutical use. Ask for the license number directly. Any reputable center will share it without hesitation.

2. NABH or JCI hospital accreditation

The National Accreditation Board for Hospitals and Healthcare Providers (NABH) is India's national hospital quality standard. The Joint Commission International (JCI) is the global benchmark and is generally considered more demanding. Either accreditation means the hospital has passed independent checks on patient safety, infection control, staff training, and clinical processes. Ask for the current accreditation certificate and its expiry date - not just a logo on a brochure or website.

3. In-house PSMA-PET imaging

Lu-177 PSMA therapy starts with a PSMA-PET scan to confirm that your cancer meets the eligibility criteria. This scan uses a radiotracer - usually Gallium-68 PSMA-11 or an F-18 PSMA agent - and requires both a PET-CT scanner and the tracer itself. Centers that offer PSMA-PET on-site can confirm your eligibility, plan your treatment, and monitor your response without referring you elsewhere. It also signals that the nuclear medicine team is trained in PSMA imaging as well as PSMA therapy - two related skills.

4. A reliable radiopharmacy and dose supply chain

Lutetium-177 decays quickly. The dose must be prepared under strict conditions and administered within a tight time window. Centers that have a dedicated on-site radiopharmacy - or a guaranteed same-day supply agreement with a licensed radiopharmacy - are far less likely to experience delays or dose inconsistencies. Ask the center how and where the dose is prepared, and what happens if a batch is delayed.

5. Volume: how many Lu-177 PSMA infusions have they given?

Volume is one of the strongest signals of real-world experience in any specialist procedure. A center that has administered hundreds of Lu-177 PSMA cycles has seen a wide range of patient profiles, side effects, and complications. It has refined its radiation safety protocols and knows how to manage bone marrow suppression, dry mouth, fatigue, and the isolation procedures patients need after each infusion. Ask the center directly: how many Lu-177 PSMA infusions has your department given in total, and approximately how many per year? A clear, specific answer is a good sign. Vagueness is not.

6. A multidisciplinary tumor board review before treatment

The best centers review each new patient's case before accepting them. This review should go beyond confirming PSMA-PET eligibility. It should look at kidney function, blood counts, prior treatment history, disease burden across all sites, and overall fitness. At minimum it should involve a nuclear medicine physician and a medical oncologist. If a center tells you it can start treatment based only on your scan images without a full clinical review, treat that as a warning sign.

7. Clear radiation safety and patient isolation protocols

After each Lu-177 PSMA infusion, you carry low-level radioactivity for several days. A responsible center will have specific procedures for post-infusion observation, written radiation safety instructions for you and your family, and clear guidance on travel, contact with children, and sleeping arrangements. Ask to see their written radiation safety protocol for patients before you travel. If no written protocol exists, look elsewhere.

8. International patient coordination team

If you are traveling from overseas, practical logistics matter as much as clinical quality. Does the hospital have a team that handles medical visa invitation letters, translated reports, airport coordination, and liaison with your home oncologist? Can they provide a written cost estimate before you arrive? These are signs of an institution that regularly treats international patients - and they reduce the risk of unpleasant surprises once you are on the ground in India.

How does the cost of Lu-177 PSMA therapy compare across countries?

Cost is one of the main reasons patients travel to India for this therapy. The table below gives a general comparison across settings. Because pricing varies between hospitals and changes over time, we use qualitative descriptions for cost rows where precise, citable figures are not available from primary sources. Always request a written itemized quote from any hospital before committing to travel. For a closer look at how pricing breaks down, the article on Lu-177 PSMA therapy cost in India vs the US covers the real numbers in more detail.

Lu-177 PSMA Therapy: Key Comparison Across Treatment Settings

Factor	India (accredited private hospital)	United States	UAE or GCC private
Cost per cycle	Substantially lower than US or GCC private settings; request a written quote in USD or INR from each hospital before traveling	Very high; a Canadian health technology assessment put the full-course cost at approximately CAD 122,489 per patient (2023 CADTH figures); US list prices are generally higher than Canadian published estimates	Generally higher than India; limited to a small number of centers; verify availability in your specific country before planning travel
Regulatory and hospital accreditation	Top centers hold AERB radiopharmaceutical licensing plus NABH accreditation; several also hold JCI accreditation	NRC licensing for nuclear medicine; JCAHO hospital accreditation standard applies	Varies by country and facility; JCI accreditation available at some larger centers
PSMA-PET imaging on-site	Available at leading centers; confirm before booking	Available at most academic cancer centers and specialist hospitals	Limited availability; some patients travel to India or Europe for the eligibility scan before returning for treatment
Typical wait from eligibility to first cycle	Often 2-4 weeks after eligibility is confirmed; varies by center volume and individual case complexity	Variable; high-demand centers have experienced supply and scheduling constraints since approval	Very limited slots; wait may be extended or therapy may not be locally available at all
International patient support	Well-developed at experienced centers: visa letters, translated reports, and coordinator teams are standard	Available but rarely designed for overseas patients; insurance navigation for non-US residents is limited	Varies significantly by facility and country; less standardized than India for traveling patients

Source for Canadian cost estimate: CADTH Pharmacoeconomic Review of Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto), NCBI Bookshelf, 2023.

The key point is this: India offers real cost savings over the US or GCC private sector without compromising clinical quality at the leading accredited centers. The key variable is which hospital in India you choose - and that is exactly what this checklist helps you assess.

Questions to ask before you book any center

A center with genuine experience in Lu-177 PSMA therapy will answer each of these questions clearly and without hesitation. Use them in any initial call or email with a hospital you are considering.

• Do you hold a current AERB license for therapeutic radiopharmaceutical administration? Ask for the license number.
• Are you NABH or JCI accredited? Ask to see the current certificate and its expiry date.
• How many Lu-177 PSMA infusions has your department given in total, and approximately how many per year?
• Do you have PSMA-PET imaging on-site? Which tracer do you use - Ga-68 PSMA-11 or an F-18 PSMA agent?
• Will my case be reviewed by a multidisciplinary team before you accept me for treatment? Who is on that team?
• Can you provide a written cost estimate before I book travel? Ask for a line-item breakdown covering the infusion itself, pre-cycle blood work, any required imaging, and any in-patient stay.
• What written radiation safety instructions do you give patients after each infusion? Can you send a copy in advance?
• Who will be my point of contact for international patient coordination? Ask for a specific name and a direct contact method.

If you want guidance on how to prepare your medical documents before approaching hospitals, the article on what to prepare for a second opinion on Lu-177 PSMA eligibility walks through exactly what to gather and how the expert review process works.

Red flags to watch for when evaluating a center

Some signals suggest a center may not have the experience or infrastructure to deliver this therapy safely. Walk away if you encounter any of the following.

• Staff cannot provide the AERB license number when asked, or claim one is not required.
• No NABH or JCI accreditation, and no clear alternative quality standard is offered instead.
• The center promises a cure, guaranteed PSA reduction, or guaranteed tumor shrinkage. Responsible clinicians use language that reflects what the research suggests - not what is certain for any individual patient.
• No PSMA-PET scan is required before treatment. Eligibility confirmation through imaging is a clinical requirement, not a step that can be skipped to speed up scheduling.
• No multidisciplinary review of your case before treatment begins. Your kidney function, blood counts, and bone marrow reserve all affect whether this therapy is appropriate for you right now.
• Cost estimates are verbal only, or figures change after you arrive. A center experienced with international patients will provide written figures in a specific currency before you book flights.
• No written radiation safety protocol exists for patients to take home after each infusion.

Your next step before traveling for Lu-177 PSMA therapy

The most important thing you can do before booking travel is to have your eligibility confirmed by an independent nuclear medicine team. This means sharing your PSMA-PET scan images, recent blood work, and full treatment history with a specialist who has no commercial interest in whether you proceed. If Lu-177 PSMA therapy is not suitable for you right now - because of PSMA-negative disease, reduced kidney function, very low blood counts, or another reason - you need to know that before you spend money on flights and accommodation. And if you are suitable, a pre-travel review gives you clarity on what to look for in an Indian center and what a realistic treatment plan should involve.

You can request a Lu-177 eligibility review through Art of Healing Cancer before committing to any hospital. Their nuclear medicine team reviews PSMA-PET scans and clinical records from patients worldwide and can advise whether treatment in India is appropriate for your specific case - including which type of center fits your disease profile. If Lu-177 PSMA therapy is not the right option at this stage, they can also advise on what alternatives may be worth exploring.

For patients with bone metastases, it is worth talking with your oncology team about bone health during the treatment period. Many patients with mCRPC ask about over-the-counter options to support bone density alongside their clinical care plan. If this is relevant to you, you can explore the Joint and Bone range at Ayurnomics for evidence-informed supplement options to discuss with your doctor before you travel.

Once your eligibility is confirmed and you have your checklist of answers from several hospitals, contact the team via the Lutetium Therapy contact form to discuss which centers in India are best matched to your case, what a realistic cost estimate looks like for your specific situation, and how to structure your travel across multiple cycles. If Lu-177 PSMA therapy turns out not to be right for you, a second opinion on alternatives is also available through that contact.

When to talk to your doctor

If your most recent PSMA-PET scan shows PSMA-positive disease and your cancer has continued to grow despite hormone therapy, ask your oncologist whether Lu-177 PSMA therapy fits your current situation and blood work. Also speak with your doctor before traveling internationally for any cancer treatment, before making changes to any current medications, and before starting any supplement - even an over-the-counter one.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.